Evaluation of Paro, a Therapeutic Assistance Robot in Analgesic Management During the Placement of a Peripheral Intravenous Line in Infants and Children.

NCT ID: NCT07299006

Last Updated: 2025-12-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-15

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Peripheral intravenous catheterization is one of the most frequently performed procedures in children in emergency rooms and pediatric units. It often causes anxiety for both the child and their parents, which increases the pain associated with the procedure itself, as fear and pain are closely linked. Managing the child's pain and anxiety is essential to optimize the child's well-being in the short, medium, and long term.

The quality of pediatric analgesia largely depends on the multimodal approach to interventions offered to children in pain. Recently, several non-pharmacological therapies for pain management and anxiety reduction have been developed. Among these techniques, new technologies have emerged, such as therapeutic assistance robots equipped with artificial intelligence, but their therapeutic benefits still need to be evaluated.

The investigators therefore aim to conduct a study on PARO, a therapeutic assistance robot shaped like a baby seal, to evaluate its role in pain management during peripheral venous catheterization in children. The investigators intend to compare the therapeutic effects of PARO combined with standard techniques versus standard techniques alone during painful procedures. The objective is to determine whether the use of this therapeutic assistance robot can improve and optimize the overall management of children undergoing needle-induced skin punctures. Thus, the investigators plan a multicenter, randomized, open-label, superiority study conducted in five pediatric centers. The investigators aim to recruit 120 infants and children aged 12 months to 7 years who will undergo peripheral venous catheterization. Pain will be assessed using the FLACC (Face-Legs-Activity-Cry-Consolability) hetero-assessment scale in this age group.

Secondary objectives include assessing and comparing distress in the two groups using the PRIC (Procedural Restraint Intensity for Children) tool, which measures restraint intensity, as well as monitoring heart rate variability, the number of attempts required to complete the procedure, parental anxiety via the STAI (State-Trait Anxiety Inventory) questionnaire, and finally, the satisfaction of both parents and paramedical staff.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain Management

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group : standard multimodal stratgey

The child will go to the emergency room. If EMLA cream is used to stop pain, it will be put on the skin 30 minutes to 1 hour before the procedure.

If MEOPA is used to help with pain, the child will wear a mask with the gas. The procedure starts by cleaning the skin and finding a vein. The procedure really begins when the needle first goes into the skin. The procedure ends when the needle is taken out and a bandage is put on

Group Type ACTIVE_COMPARATOR

non- pharmacological interventions and usual pharmacological interventions

Intervention Type DRUG

Pharmacological therapies : EMONO and EMLA cream EMONO = Equimolar Mixture of Oxygen and Nitrous Oxide EMLA cream = Eutectic Mixture of Local Anesthetics cream Non-pharmacological interventions (include music therapy and watching cartoons).

tes group: standard multimodal Strategy with PARO robot

The child will be taken to the emergency room. If EMLA cream is used to reduce pain, it will be put on the skin 30 minutes to 1 hour before the procedure.

To help the child feel comfortable with PARO, the robot will be placed on or next to the child's lap 15 minutes before the procedure starts.

If MEOPA is used to relieve pain, the mask with the gas will be put on the child's face.

The procedure will start with cleaning the skin and looking for a vein. The procedure officially begins when the skin is first pierced. The procedure will finish when the needle is taken out and a bandage is put on.

Group Type EXPERIMENTAL

Test group : standard multimodal strategy with PARO robot

Intervention Type DEVICE

The child will be taken to the emergency room. If EMLA cream is used to reduce pain, it will be put on the skin 30 minutes to 1 hour before the procedure.

To help the child feel comfortable with PARO, the robot will be placed on or next to the child's lap 15 minutes before the procedure starts.

If MEOPA is used to relieve pain, the mask with the gas will be put on the child's face.

The procedure will start with cleaning the skin and looking for a vein. The procedure officially begins when the skin is first pierced. The procedure will finish when the needle is taken out and a bandage is put on.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Test group : standard multimodal strategy with PARO robot

The child will be taken to the emergency room. If EMLA cream is used to reduce pain, it will be put on the skin 30 minutes to 1 hour before the procedure.

To help the child feel comfortable with PARO, the robot will be placed on or next to the child's lap 15 minutes before the procedure starts.

If MEOPA is used to relieve pain, the mask with the gas will be put on the child's face.

The procedure will start with cleaning the skin and looking for a vein. The procedure officially begins when the skin is first pierced. The procedure will finish when the needle is taken out and a bandage is put on.

Intervention Type DEVICE

non- pharmacological interventions and usual pharmacological interventions

Pharmacological therapies : EMONO and EMLA cream EMONO = Equimolar Mixture of Oxygen and Nitrous Oxide EMLA cream = Eutectic Mixture of Local Anesthetics cream Non-pharmacological interventions (include music therapy and watching cartoons).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. are between 12 months and 7 years old
2. require a peripheral intravenous catheterization (PIC)
3. speak and understand French.

Exclusion Criteria

1. the need for contact isolation including colonization or infection with multidrug-resistant bacteria (MRB),
2. visual or hearing impairment;
3. psychiatric pathology that could impair the understanding;
4. life-threatening emergency;
5. the requirement for stronger analgesic drugs (such as Morphine, Ketamine, and intranasal therapeutics).
Minimum Eligible Age

1 Year

Maximum Eligible Age

7 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fondation Lenval

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Barbara LE GALLO, MD

Role: PRINCIPAL_INVESTIGATOR

Hôpitaux pédiatrique Nice CHU Lenval

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fondation Lenval Hôpitaux pédiatrique Nice CHU Lenval

Nice, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

ALINE JOULIE, PHD

Role: CONTACT

Phone: +33492030520

Email: [email protected]

Jennifer BATTISTA, MD

Role: CONTACT

Phone: + 33 6 36 80 27 42

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-A00617-42

Identifier Type: OTHER

Identifier Source: secondary_id

24-HPNCL-05 PARO

Identifier Type: -

Identifier Source: org_study_id